Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell · B-Lymphocytic Leukemia, Chronic · B-Cell Chronic Lymphocytic Leukemia · Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma · Leukemia, Acute Lymphoblastic · Small Lymphocytic Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (NCI Medical Oncology Referral Office) · ncimo_referrals@nih.gov · 240-760-6050
Study leads
James N Kochenderfer, M.D.
Principal Investigator
National Cancer Institute (NCI)